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INTRODUCTION

Eosinophils have long been asociated with parasitic and

allergic diseases.

Methods of procurement and purification of

eosinophils in the last ten years have allowed intensive

investigation into their components, properties, runctions, and
mechanisms (Gleich et al, 1982).

The qranule of the eosinophil is distinctive, indicating that

a study of the proteins contained in the granule might shed light
on the functions of the eosinophil.

Major basic protein (MBP) has

been isolated from the core of the granule and eosinophil cationic

protein (ECP) and eosinophil-derived neurotoxin (EDN) from the
matrix of the granule (Ackerman et al, 1983).

All three proteins

are distinctive and have been isolated to homogeneity.

Separation of eosinophils over discontinuous gradients has
shown that eosinophils present in the bloodstream are of varying
densities and that eosinophils of patients with eosinophilia tend
to be less dense than those of normal persons (Wingvist et al,

1982).

A quantitative investigation of three distinctive granule

proteins may assist in determining the reasons for density
variations and for the differences between the eosinophils of

patients with eosinophilia and those of normals.
The qoals of this proiect are to separate eosinophils in
blood samples taken from patients with eosinophilia and from

normals based on density over discontinuous Metrizamide gradients;

to determine quantitatively the levels of the three distinctive

proteins of the eosinophil, specifically MBP, EDN, and ECP; and to
compare the levels of these proteins found in eosinophils of

patients with eosinophilia to the amounts found in corresponding
density eosinophils of normal persons.
Procurement and Purification

Until 20 years ago, the ability to study eosinophils was

hampered by the lack of procurement techniques.

The number of

eosinophils required for testing was greater than the number
available in untreated animals.

Archer and Hirsch (1963)

developed a method for increasing the number of eosinophils to
levels suitable for study.

.7

Using this method, an average of 4x10

eosinophils per guinea pig were produced (Gleich and Loegering,
1973).

Briefly this involved repeated saline lavages of the

peritoneal cavity. This method is preferred to intraperitoneal

injections with antigens in that the eosinophils of antigen
treated animals were contaminated by neutrophils and the mortality

rate of antigen treated animals was greater than nonantigen
controls (Gleich et al,

1983).

Furthermore, animals lavaged
7

weekly with saline produced 2-6x10
long as six months (Gleich et al,

eosinophils per lavage tor as
1983).

More recently the effectiveness of horse serum induced

peritoneal eosinophilia has been studied (Gleich et al, 1983).
Eighteen to 24 hours after an injection with 1.5 ml of horse
serum, the peritoneal cavities of guinea pigs were lavacred with 50
ml

saline.

This produced a ten-fold increase in eosinophils over

saline lavage only. These preparations contained up to 30%
neutrophils however, making them less valuable for certain
studies.

Peritoneal lavage following infection with a helminth

parasite has been used to produce eosinophils in mice and rats
(Archer and Hirsch, 1963; MacKenzie et al, 1977).

Eosinophils

increasd in mice infected with Schistosoma mansoni or Trichine11a
spiralis bv approximately 25% following a proteose-peptone

injection (James et al, 1979).

A yeild of 30-35xlOw eosinophils

per animal was obtained using this technigue.
infected mice produced approximately 50x10

nucleated cells,

whereas normal mice produced less than 5x10

1979).

Mesocestoides corti

cells (Johnson et al,

Again these exudates consisted of a variety of leukocytes,

however eosinophils constituted the major fraction.

Lopez et al. (1981) demonstrated that M. corti produced more
eosinophils that either T. spiralis or Taenia crassiceps.
Pretreatment with cyclophosphamide has also been used to produce

blood eosinophilia to nonparasitic antigens (Vadas, 1982).

Eosinophils have also been procured from cows either injected
with Ascaris suum or infected with metacercariae of Fasciola
hepatica (Grewal and Babiuk, 1979; Duffus et al, 1980).

Portman

et al (1980) and others have collected large volumes of blood as a

means of obtaining human eosinophils from patients with marked
eosinophilia.

Eosinophils can be procured with, in some cases,

little need for purification (Gleich et al, 1976; Kater et al,
1976; Metcalfe et al, 1977).

Gleich et al (1981) procured up to

l.SxlO11 eosinophils using cytapheresis.

In this procedure, whole

blood is separated into its components on the basis of density
differences in the gravitational field created within a rotating

centrifuge bowl (Pineda et al, 1977).

In over 30 cases using

cytapheresis to remove eosinophils, no patients have experienced
either harm or benefit as a result of eosinophil removal (Gleich

et al, 1983).

Gleich et al (1983) suggest this is due to the

ability of bone marrow to generate far greater numbers of
eosinophils than can be removed by current techniques.
A number of methods for purificaton of eosinophils have been

attempted, but most have produced nonviable cells, low yields, or

highly impure preparations (Behrens and Marti, 1954; Lindahl and
Lindahl, 1955; Behrens and Marti, 1955; Esselier and Marti, 1955;
Archer and Hirsch, 1963).

Eosinophils have been successfully

separated from other cells on the basis of cell adherence,

phagocytosis, autofluorescence, and cell density (Gleich et al,
1983).

Using a three step method, Parillo and Fauci (1973) have
obtained from normals, eosinophil slurries of 51-93% purity and

yields of 25-52%.

Granulocytes are separated first from

mononuclear cells by centrifugation over a Ficoll-Hypaque cushion
then from ertyhrocytes by dextran sedimentation and hypotonic

lysis.

The resulting granulocytes are then separated over a nylon

wool column which traps neutrophils and releases eosinophils.

A

modification of this technique was used by Parillo and Fauci

(1978) to produce 89-99% pure eosinophils with yields of 28-69%
from patients with eosinophilia.

Gleich et al (1983) have used

this procedure to separate eosinophils from contaminating

neutrophils in slurries obtained from guinea pig peritoneal
cavities, but were unable to separate eosinophils from neutrophils
of patients with eosinophilia.

Yields of 21-80% eosinophils with 50-90% purity were obtained

utilizing neutrophil and monocyte adherence via Fc binding sites
to petri dishes coated with suitable binding complexes (Tai and
Spry, 1977). Others have removed mononuclear cells from
eosinophils onto glass then plastic petri dishes (Butterworth et
al, 1976; Grewal and Babiuk, 1979).

Following separation from other blood fractions, granulocytes

have been separated based on phagocytosis (Sher and Glover, 1976).
In this procedure neutrophils which readily phagocytize carbonyl
ion, can be pulled from a mixed granulocyte suspension using a

magnet. The resulting eosinophils, average 90% purity, remain in
suspension.

Eosinophil granules contain a factor which causes

autofluorescence of the cell (Fuerst and Jannach, 1965).

Using a

fluorescence activated cell sorter (FACS II), Weil and Chused

(1981) were able to separate high purity eosinophils with a yield
of about 65%.

Of those separation techniques employed today, the majority
take advantage of the high density of the eosinophil (Gleich et
al, 1983).

The first studies of eosinophil granule protein

employed sodium metrizoate (Day, 1970; Gleich and Loegering, 1973)
or sodium diatrizoate cushions (Gleich et al, 1976).

greater than 90% were obtained using these methods.

Purities

Yield ranged

from 39-63% and contained neutrophils which were difficult to

separate from the eosinophil layers (Day, 1970: Gleich et al.
1976).

Eosinophils separated by this method were viable and

displayed motility, however the cushions were hypertonic which
could have modified the cells.

Isotonic Ficoll-Hypaque discontinuous gradients were employed

to successfully separate eosinophils from other cell fractions of

dog, mouse, and bovine samples (Muscoplat et al, 1977; Kazura and
Grove, 1978; Duffus et al, 1980).

Consecutive centrifugations

through Ficoll-Hypaque were applied to separate human eosinophils
(Novato-Silva et al, 1980; Tai and Spry, 1980; Le et al, 1982).
Vadas (1979) showed that even the most pure Ficoll-Hypaque

obtained fraction contained 12% neutrophils.

While it is less

useful than other methods in separating neutrophils from

eosinophils, its simplicity makes it attractive when sorting only
mononuclear cells from the substantially higher density
eosinophils.

Eosinophils have successfuly been separated from other cells
based on their ability to penetrate a cushion of erythrocytes

(Jorg et al, 1978).

This method has provided preparations of

90-98% with yields of 45-55% (Portmann et al, 1980).

The

effectiveness of this method is overshadowed by its demand for

large quantities of blood, 20 liters of horse blood (Jorg et al,
1978) and three liters of human blood (Portman et al, 1980).

Separation over Percoll, the trade name for colloidal silica

particles coated with polyvinylpyrrolidone, provides yields of
86-99% pure eosinophils in an isotonic environment (Pertoft et al,
1978; Gartner, 1980).

Gartner (1980) showed that leukocyte

slurries, separated from erythrocytes by dextran sedimentation,
contained a band of eosinophils at the 1.090-1.095 gm/ml

interface, neutrophils at 1.080-1.085 gm/ml, and mononuclear cells

and basophils at 1.070-1.080 gm/ml when separated over Percoll

gradients.

DeSimone et al (1982), using a modification of this

techique found that eosinophils of patients infected with
helminths separated in bands of lighter density.
Metrizamide, 2-(3-acetamido-5-N-methylacetamido-2,4,6-

tri-iodobenzamido)-2-deoxyglucose is a medium which offers high

yield eosinophils while being only slightly hypertonic.

Though

the hypertonicity is an important consideration when studying the
function of the eosinophil, it appears to have little if any

effect on the protein content of the granules.

Sanderson and

Thompson (1978) introduced the use of Metrizamide for purification
of rat eosinophils, neutrophils, mast cells, and macrophages.

Using a two step gradient, they successfully separated eosinophils
to a purity of 95% or higher.

Discontinuous gradients of

Metrizamide were used by Ross et al (1978) and Winchester et al

(1978) to separate bone marrow cells, Vadas (1979), using a
modification of these techniques in which gradients were formed by
Metrizamide concentrations of 18, 20, 22, 23, 24, and 25%,
obtained 90-100% pure eosinophils.

As judged by trypan blue exclusion, the eosinophils were
viable and were furthermore able to kill the schistosomules of £L_

mansoni as determined by the release of
schistosomules (Vadas et al, 1979)/
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Cr from labeled

Since then, a number of

laboratories have used Metrizamide as a means to separate

eosinophils and other leukocytes (see Gleich et al, 1983 for
review).

Maior Basic Protein

Gleich and co-workers liberated granules from purified guinea

pig eosinophils by repeated mechanical agitation and dissolved the
granules in weak hydrochloric acid to release the contents (Gleich
et al, 1973).

The lysed granules were analyzed by polyacrylamide

electrophoresis in urea and on SDS gels, by electric focusing, and
by fractionation over columns of Sephadex G-50.

These tests

indicated a broad protein band, basic in nature, which absorbed
over half the Coomassie brilliant blue and over half the analine
blue black stain bound to the gels.

peroxidase activity.

The band was found to have no

Further studies showed that this protein,

identified as major basic protein (MBP), had a molecular weight of
11,000 with a tendency to polymerize when concentrated or stored

prior to analysis (Gleich et al, 1979).

Treatment of MBP with a

reducing agent such as dithiothreitol (DTT) depressed

polymerization.

MBP also maintained its monomeric form when

alkylated with iodoacetamide.

MBP was distinguished from histones in that it contains four

percent tryptophan, while histones contain no tryptophan residues
(Wilhelm et al, 1971).

Amino acid analysis also showed that MBP

contained 13% arginine contributing to he basicity of the protein
(Gleich et al,

1974).

The ability of dithiothreitol, a

disulfide-reducing agent, to depolymerize MBP indicated that the

protein contained free sulfhydryl groups.

Further study showed

that two free sulfhydryl groups were present (Gleich et al, 1980).
Finally, the molecule contained six moles of half cysteine.

Major basic protein was distinguished from the cationic
proteins of the neutrophil granule in a series of experiments
(Janoff and Zweifach, 1964; Seegers and Janoff, 1966; Zeya and

Spitznagel, 1966A; Zeya and Spitznagel, 1968).

While neutrophil

basic proteins increased vascular permeability and caused guinea

pig ilium to contract, MBP did neither.
histamines or bradykinin.

Nor did MBP inhibit

Finally, MBP differed from the basic

proteins of the neutrophil (Zeya and Spitznagel, 1966B; Zeya and
Spitznagel, 1968) in that it exhibited little antimicrobial
activity (Gleich et al, 1974).

Further characterization of MBP showed that it is able to

interact with acidic molecules, could activate papain, contained

no enzymatic activity, neutralized the anticoagulant activity of
heparin, and prolonged clotting time when added to guinea pig
blood (Gleich et al,

1974).

Immunofluorescence studies have shown the ability of the

eosinophil to deposit MBP into surrounding tissue during

diapedesis (Ackerman et al, 1983).

This property along with the

ability of MBP to react with acidic groups on cell membranes
indicates that MBP may alter membrane properties thus playing a
role in biological reactions (Osserman et al, 1973).
The incedence of well studied parasitic infections and the

presence of an immunoglobulin E (IgE)-producing tumor make the rat
a particularly useful species for studying the function of the

eosinophil (Ogilvie and Jones, 1971; Mahmoud et al, 1975; Bazin et
al, 1974).

Lewis and associates (1976) interested in the

interactions of eosinophils and IgE in allergic and parasitic

diseases, isolated and characterized a rat eosinophil protein

similar to the MBP previously isolated in guinea pigs and humans.

The molecular weight of this protein was found to be 11,000, the

isoelectric point greater than 10, and the amino acid composition

quite similar to that of guinea pig and human MBP.

A comparison

of the amino acid composition is shown in Table 1 (from Lewis et
al,

1976).

Wassam and associates (1979) developed a sensitive

raidoimmunosassay for MBP which detected levels of MBP as low as 2

ng/ml in body fluids and tissues.
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The assay utilized

rabbit anti-MBP, and burro anti-rabbit IgG.

I-MBP,

Iodoacetamide induced

alkylation prior to labeling and the presence of protamine,
another basic protein, in the phosphate buffer were conditons

necessary for the assay.

Wassom et al (1979) also found that

polymerized or native MBP were immunologically inactive as

compared to alkylated or reduced and alkylated MBP.

Reduction

with DTT followed by alkylation of inactive MBP restored
reactivity.

To determine the location of MEP within the granule of the

eosinophil, Lewis and co-workers (1978) employed both

polyacrylamide gel electrophoresis on isolated granule

crystalloids and immunoelectronmicroscopy.

Early studies

indicated that MBP was located in the core of the eosinophil

granule (Gleich et al, 1973).

This conclusion was based on the

following observations: first, in electron photomicrographs, the
core appeared to be a major component of the granule; second, the
regular structure of the core indicated that it was formed of a

single constituent (Miller et al, 1966); and third, the lack of
peroxidase activity in the granule core (Gleich et al, 1973;
Cotran and Litt,

1969)

Purified granules and intact eosinophils both fixed in
formalin, were exposed to 10% acetic acid to inactivate inherent

peroxidase activity.

The samples were then treated with anti-MBP

as the first stage antibody and stained by the immunoperoxidase

procedure (Miller et al, 1966).

Peroxidase reaction product was

observed in the core of the granule (Lewis et al, 1978).

This

observation was complemented by examination of the electron

micrograph negatives by a spot densitometer.

Density difference

between the core and the matrix showed that the core was more

dense.

In a control using normal rabbit serum as the first stage

antibody, the matrix stained more dense than the core (Lewis et
al, 1978).

This control indicated the specificity of anti-MBP.

In further experiments, cores were isolated from granules

using the method described by Gessner and co-workers (1972).

The

procedure was modified using purified granules as the starting
material rather than intact eosinophils.

The purpose of this

change was to rid the core sediment of unwanted organelles.

The

resulting cores, rectangular with irregular edges, were analyzed

by physiochemical and immunochemical methods (Lewis et al, 1978).
SDS-Page analysis showed that the MBP band absorbed approximately
84% of the bound dye.

Double antibody radioimmunoassay showed no

difference between the inhibition caused by MBP and that caused bv
the granule core.

Biuret analysis using human serum albumin as a
1%

standard showed the extinction coefficient, E ° at 277 nm, of MEP

to be 26.3 (Gleich et al, 1974).

Under the same analytical

conditions, the extinction coefficient of the core protein was

shown to be 26.8 + 1.0 (X + SEM) indicating that the core protein
is

MBP.

Studies by Mahmoud and associates have shown that treatment
of mice with anti-eosinophil serum increases susceptibility to

infections by Schistosoma mansoni and Trichinella spiralis
(Mahmoud et al, 1975A; Mahmoud et al, 1975B; Grove et al, 1977).
Schistosomules of S. mansoni and newborn larvae of T\ spiralis

were shown to be damaged in vitro by purified eosinophils
(Butterworth et al, 1975; Butteworth et al, 1977; Ramalho-Pinto et

al, 1978; Kazura and Grove, 1978; Perrudet-Badoux et al, 1978)

indicating that resistance to these parasites involves eosinophil
responses.

Butterworth et al (1979) have shown that the

schistosomules of S. mansoni are damaged in vitro by purified

guinea pig and human MBP.

Likewise, newborn larvae of T. spiralis

are damaged by MBP (Wassam and Gleich, 1979). Furthermore,
eosinophils were shown to adhere irreversibly to schistosomules in

the presence of antibody (Vadas et al, 1980) and the amount of
adherence increased in the presence of MBP (Butterworth et al,

1979).

Together these studies suggest the role ot MBP in the

parasite defense mechanism. Electronmicroscopic inspection of

schistosomule damage £>y eosinophils suggests that the contents of
eosinophil granules are issued onto the membrane of the parasite
(Gluaert et al,

1978; McLaren et al,

1978).

The toxicity of MBP to murine ascites cells was also
demonstrated (Butterworth et al,

1974) leading to the question of

the ability of MBP to damage cells of organs with elevated
eosinophil distribution.

MBP was shown to damage intestine,

spleen, skin, and peripheral blood mononuclear cells in a dose
related fashion (Gleich et al, 1979).

Radioimmunoassay studies

showed sera concentrations as high as 14 ug/ml in patients with
asthma.

These concentrations were as high as or higher than

levels necessary to damage cells in vitro (Gleich et al, 1979).

Of particular interest is the cytotoxicity of guinea pig MBP
to tracheal epithelium.

Frigas and co-workers (1980), using phase

microscopy, demonstrated ciliostasis in circumscribed areas 48
hours after treatment with as little as 10 ug/ml MBP.

One hundred

ug/ml concentrations of MBP slowed ciliary beating within three
hours and produced ciliostasis within 23 hours.

At low

concentrations (10 ug/ml) MBP caused damaged cells to be released
into the lumen.

Higher concentrations stripped all but the basal

eels, altered the structure of the expurged cilia, and produced

edema in the lamina propria (Frigas et al, 1980),
(1980)

Gleich et al

draws attention to the similarities between MBP-treated

tracheal epithelium and the pathology of patients with bronchial
asthma (Hilding, 1943; Cardell and Pearson,
Dunnili,

1971;

Cutz et al,

1959; Naylor,

1962;

1978).

EOSINOPHIL CATIONIC PROTEIN

Olsson and Venge (1972, 1974)

isolated and separated a number

of cationic proteins from leukemic myeloid cell granules.

One

group of proteins showed close correlation to the eosinophil

counts of healthy subjects (p<0.001).

These proteins, designated

"eosinophil cationic proteins" constitute approximately 30% of the

eosinophil granule.

The proteins were further localized by

comparing their distribution to the densities at which suspect

protein sources were concentrated when subjected to velocity
centrifugation (Olsson et al, 1977).

The results demonstrated

that the cationic proteins were packaged within the eosinophil
granule.

The most abundant of the eosinophil cationic protenis (ECP)

has a molecular weight of 21,000 as shown by sodium odcyl sulfate

polyacrylamide gel electrophoresis (Olsson and Venge, 1974).
Although ECP is composed of more acidic amino acids than basic,
the isoelectric point is greater than 11, partly due to the

masking of carboxylic acid groups.

The protein contains 11%

arginine and 10 half-cysteines and embody 2.5 moles of zinc per
mole of protein (Venge et al, 1980).

While ECP exhibits some of

the same properties as MBP, recent studies have verified that the
two are distinct (Gleich and Venge,

to be published).

Eosinophil cationic proteins did not cause hydrolysis of
BTEE, BAEE, TAME, or BAA indicating a lack of esterase activity

(Olson et al, 1977).

They failed to cause contraction of guinea

pig ileum and did not exhibit antihistamine activity nor inhibit
guinea pig anaphylatoxin.

When tested against Escherichia coli

and Staphylococcus aureus, no bactericidal activity was observed.

Eosinophil cationic protein does however affect the coagulation
system a number of ways.

Coagulation time of normal plasma

ecreased in a dose-dependent manner with ECP (Venge et al,

1979).

Preincubation of plasma with ECP (>100 ug/1) for 0.5-4 minutes

promoted coagulation, yet extended preincubation increased
clotting time (Venge et al, 1979).

The recalcification time of

factor Xll-deficient plasma was prolonged in the presence of ECP,
but that of factors V,

VII,

VIII,

IX, X,

and XI was shortened.

Eosinophil catinic protein also assisted in the activation of
factor Xll-dependent Kallikrein.

Together these suggested that

the role of ECP in the coagulation pathway is focused on factor
XII.

The activation of plasminogen by urokinasse was enhanced by
ECP indication that ECP is also a factor in fibrinolysis (Dahl and

Venge, 1979).

Crossed immunoelectorphoresis indicated that ECP,

particularly in a 1:1 molar relationship with plasminogen, alterd
the conformation of

the plasminogen molecule (Venge et al,

1980).

No complex formation has been demonstrated between the proteins

(Dahl and Venge, 1979).

It has also been suggested that ECP may

play a role in the humoral controls of inflammation (Venge et al,
1980).

While ECP levels correlated closely with the number of

blood eosinophils, Benge et al (1980) point out that to little is
known about

the CP turnover

in

circulation and about

the

effects

of physiological and pathological changes on ECP levels.

Furthermore, the abundant noncirculation eosinophils may
contribute to serum ECP levels (Osgood et al,

1954).

MATERIALS AND METHODS

Patient

Samples and Normal

Controls

One volume of 6% Macrodex

Laboratories, Piscataway,

NJ)

(Macrodex-dextran 70,

PHarmacia

in normal saline was mixed with five

volumes of freshly drawn heparinized blood from patients or

normals.

This was allowed to settle for one hour at 37°C.

The

leukocyte rich supernatant (buffy coat) was removed, diluted 1:1
with Minimum Essential Medium (MEM)

(Gibco, Grand Island, NY)

containing 10% heat inactivated fetal calf serum and 3% (w/v)
DNase (MEM/FCS/DNase), and centrifuged at 400 g for 10 minutes.

The pellets were washed twice with MEM/FCS/DNase.

The washed

pellets were resuspended in 4 ml MEM/FCS/DNase and counted on a

hemacytometer using Randolf's phloxine and methylene blue stain to
determine the number of eosinophils as well as total leukocytes in

the buffy coat.

The cells were diluted with MEM/FCS/DNase to a
7

concentration of 2.5-5x10

leukocytes/ml.

Preparation and Standardization of Metrizamide Gradient Solutions

Human eosinophils were separated on the basis of density over

Metrizamide gradients as described by Vadas et al (1979).

Stock

Tyrodes solution (5x) was prepared by adding 5 gm dextrose, 5 gm
sodium bicarbonate, I gm potassium chloride, 40 gm sodium

chloride, and 0.25 gm sodium phosphate monobasic (anhydrous).

Tyrodes gel/DNase is prepared by dissolving 0.5 gm Bloom's gelatin

(Fischer, Itasca, ID in 100 ml steaming d'H20 and adding to this
100 ml Tyrodes stock solution (5x), 300 ml d*H20, and 15 gm DNase
(Sigma Chemical Co., St. Louis, MO).

The solution was Millipore

filtered and stored under sterile conditions at 4 C.

A 30% (w/v) Metrizamide (analytical reagent grade, Nyegaard &
Co. A/S, Oslo, Norway)

gel/DNase.

stock solution was prepared in Tyrodes

The density as determined using a 5 ml pycnometer and

adiusted with Tyrodes gel/DNase to 1.165 gm/ml.

The 30% stock was

diluted to 18, 20, 22, 23, 24, and 25% (w/v) with Tyrodes

gel/DNase.

The density of each solution was determined by

pycnometry and the refractive index of each by refractometry.

The

density and refractive index data from several preparation was
collected to determine the equation of the line that characterizes

their relationship.

Using this equation, the density of fuure

preparations was determined and adjusted using refractometry
alone.

Separation of Eosinophils by Density

Discontinuous gradients of 18, 20, 22, 23, 24, and 25% (w/v)
solutions of Metrizamide in Tyrodes gel/DNase were poured into 15
ml conical screw cap centrifuge tubes using a multichannel

peristaltic pump.

Two milliliters of suspended buffy coat cells

were pumped onto each gradient tube.

The tubes were centrifuged

at 1200 g, calculated at the 22-23% interface, for 45 minutes

using a centrifuge with a swinging bucket head, and anonflexible
shaft.

The cell layer that forms at each graditne interface was

collected using a traight blunt-end 19 guage needle attached to a

5 ml syringe.

To avoid contamination with lighter density cells,

the cells that adhere to the wall of the tube and those missed by

the 19 guage needle were collected with a 17 guage needle and
discarded before harvesting the next interface.

The cells of

corresponding interfaces were pooled and diluted 1:3 in
MEM/FCS/DNase.

The pools were washed twice and resuspended in

MEM/FCS/DNase and counted on a hemacytometer using Randolf's

phloxine and methylene blue stain.

Twenty microliters of each pool were removed for

cytocentrifugation.

The remainder of each pool was diluted to 10

ml in phosphate buffered saline and centrifuged at 400 g for 10

minutes.

The pellets were resusupended in 0.1 M Na2HP04~ KH2P04

buffer, pH 7.4, containing 1 ng.ml protamine sulfate, 0.5% fetal

calf serum, 0.1% Nan3, and 10 mM ethylenediamine tetraacetate
(PPF-E buffer) with 1% Triton X-100 and cryopreserved in liquid
nitrogen.

Microscope slides were coated with protein by pipetting 90
microliters of MEM/FCS/DNase into cytocentrifuge blocks and

spinning briefly.

Ninety microliters MEM/FCS/DNase is then placed

in each well, along with 10 microliters suspended cells from pools
folowed by 90 microliters MEM/FCS/DNase.

The cells were spun at

200 g for five minutes forming an even coat of cells on the slide.
The slides were stained with Wright's stain and a differential
cell count is performed on each slide.

Preparation of Cell Extracts

Cell suspensions in PPF-E with 1% Triton X-100 were removed

from liquid nitrogen, thawed at room temperature, and transferred
to 12x75 mm glass tubes.

The tubes were rapidly frozen n a bath

of acetone and dry ice, thawed in a 37°C water bath, and vortexed
(Wassom et al, 1981).

This procedure was repeated nine times.

The extracts were clarified by centrifugation in 1.5 ml Brinkman

microcentrifuge vials at 12,000 g for seven minutes.

Double Antibody Radioimmunoassay for MBP

Radioimmunoassays for MBP, EDN, and ECP were performed using

modifications of previously described methods (Wassom et al, 1979;
Wassom et al, 1981).

MBP contains two free sulfhydryl groups and

readily forms polymers.

Monomeric MBP was isolated by reduction

with 0.13 ml of a reduction and alkylation buffer (R&A buffer)

consisting of 0.12 M NaCl, 0.01 M disodium ethylenediamine
tetraacetate (Fisher), and 0.33 M Tris (hydroxy-methylaminomethane

(Trizma base, Sigma), pH 8.0.

Twenty microliters of 0.1 M

dithiothreitol in R&A buffer was added and the solution was
allowed to incubate for one hour at room temperature.

Iodoacetamide, 0.02 ml of 0.2 M in R&A buffer, is added and the
incubation continued for 30 minutes at room temperature.

A standard curve of concentration ranging from 3 to 100 ng/ml

MBP was prepared by diluting MBP standard of known concentration
with PPF-E buffer.

Totubes containing 0.1 ml rabbit antihuman

MBP, 1/5000 in PPF-E buffer, and 0.5 ml PPF-E buffer, o.l ml of
each standard curve concentration was added.

To assure

consistency between assays, internal standards of RF clotted

plasma and DL serum were counted.

Reduced and alkylated extracts

were diluted further in PPF-E buffer then added to tubes

containing 0.1 ml rabbit antihuman MBP, 1/5000 in PPF-E buffer,
and0.5 ml PPF-E buffer.

30 minutes at 37°C.

The solutions were allowed to ncubate for

125I-labeled MBP, 7.5 ng/ml in PPF-E buffer

is added in 0.1 ml portions to all tubes.

The labeled extracts

were allowed to incubate overnight at 4 C.

Burro antirabbit gamma G, 0.2 ml neat centrifuged with 0.1%

NaN?, was added to each tube followed by normal rabbit serum, 0.1
ml 1/2000 in PPF-E buffer.

The tubes were allowed to incubate at

4°C for 2 2/2 to 3 hours then centrifuged at 1900 g for 20
minutes. The supernatants were drained and the sediment counted on
a gamma scintillation counter.
Double Antibody RIA for EDN

One hundred microliters of EDN solutions ranging from 1 to

200 ng/ml in PPF-E buffer prepared form an EDN standard of known
concentration were added to tubes containing 0.1 ml rabbit

antihuman EDN, 1/2000 in PPF-E buffer, and 0.5 ml PPF-E buffer

creating a standard curve.

RF and DL standards and freeze-thawed

eosinophil extracts were added to tubes containing 0.1 ml rabbit
antihuman EDN, 1/2000 in PPF-E buffer, and 0.5 ml PPF-E buffer.
The solutions were allowed to incubate at 37 C for 30 minutes.

Radiolabeled ,ocI-EDN, 7.5 ng/ml n PPF-E buffer was added in 0.1
12b

ml portions to all tubes.

The labeled solutions were incubated at

4°C overnight.
Burro antirabbit gamma G,

0.2 ml neat centrifuged with 0.1%

NaN3 and normal rabbit serum, 0.1 ml 1/2000 n PPF-E buffer were
added to each tube and the solutions allowed to incubate at 4 C

for 2 1/2 to 3 hours.

The preparations were centrifuged at 1900 g

for two minutes, the supernatants were drained, and the sediments
counted on a gamma scintillation device.
Double Antibody RIA for ECP

RIA for ECP was performed in the same manner as descrived for
EDN with the exception tha ECP standard was used in place of EDN
standard,
d

rabbit antihuman ECP was substituted for rabbit

ntihuman EDN, and "^I-ECP was used for labeling.

RESULTS

Comparison of Eosinophilic Patients/ and Normals' Eosinophil
Density

To determine the density of peripheral eosinophils, buffy
coat cells of normals and eosinophilic patients were centrifuged

over discontinuous gradients of Metrizamide.
information is summarized in Table 1.

Leukocyte separation

In both normals and

patients, mononuclear cells and basophils were recovered in the
layers formed above the 18 and 22% Metrizamide gradients.
Neutrophils congregated primarily at the 22% interface and to a
lesser extent in the layers formed above the 20 and 23% gradients.

Though relatively few neutrophils were dense enough to migrate to
the 24 and 25% gradients, they accounted for 95.4

+

7.0 (mean

+

SD) percent of the noneosinophils in these layers.

The eosinophils recovered from normals consistently peaked in

the layers formed above the 23 or 24% Metrizamide gradients (Figs.
1-4).

The 23% fraction demonstrated 59

purity.

21 percent eosinophil

The 24% interface contained fewer contaminating

neutrophils demonstrating eosinophil purities of 90
Of those cells present in the 25% interface, 88

eosinophils.

5 percent.

8 percent were

Rarelv did individual neutrophils or mononuclear

cells contaminate the 25% interface.

Rather, these cells tended

to aggregate in small clusters.

The eosinophil separation of Patient #1, affected by food
allergies having 24% peripheral eosinophils, followed closely the

pattern of normal individuals (Fig. 5).

The number of eosinophils

recovered from the 18, 20, 22, and 23% layers of the patient were

Number of Eosinophils Recovered by Density Layer

NORMALS

1.31

1.62

1.57

PATIENTS

1.68

1.74
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Percent Eosinophils of Eosinophils Recovered

NORMALS

1.31

PATIENTS

1.57

1.62

1.68

1.74

1.75
1.66

18*

0.89

0.00

6.50

0.00

1.17

20^

0.00

1.38

1.77

0.00

2.39

22^

7.95

33.86

5.61

15.14

11.34

43.21

23*

63.76

36.53

29.37

4.62

72.26

2.72

2ty/o

24.16

27.02

4-8.97

57.09

12.85

1.24

25%

3.26

1.20

7-78

23.08

N.D.

Table

2

51.2

N.D.

an average of 2.45 (range 1.27 - 3.87) times the number recovered
from the corresponding layer on normal samples (Table 2).

The 24%

patient interface contained 0.8 times fewer cells than the average
24% normal pool.

Patient #2, affected by hypereosinophilic syndrome with 64%

peripheral eosinophils, showed a marked increase in both the
absolute number of low density eosinophils and the number of the

low density eosinophils in respect to the number of normal density

eosinophils (Table 2).

Eosinophil increases of 19.2, 49.4, and

1.3 times normal subjects' values were observed in the 18, 22, and

23% pools respectively.

The 20% Metrizamide interface

demonstrated an 846 fold increase in eosinophils over the normal

average, accounting for 51.2% of the eosinophils recovered (Fig.
6).

As with Patient #1,

the 24% interface contained 0.8 times

fewer eosinophils than the corresponding layer of normals.
Comparison of Patients' and Normal Subjects' Eosinophil
Distinctive Cationic Protein (DCP)

Levels

Corresponding density layers from the gradient tubes of each

subject were combined and the protein extracted by repeated,
consecutive freezing and thawing.

The extracts were analyzed for

MBP, ECP, and EDN content by double antibody radioimmunoassay

(RIA).

In both patients and normals, the concentration of EDxM was

consistently greater than those of MBP or ECP (Figs. 7-11).
The levels of MBP and ECP were similar in the 18,
25% fractions of all normals and of Patient #1.

23,

24, and

In normal

subjects, the concentrations of MBP ranged from less than 1% to
59% those of ECP in the 20% layer and ranged from less than 1% to

DIST OF EOS BY % METRIZ. (1.75)

Ld
&.
Ld
>
O
U
Ld
a:

cn
O
Ld

55

t

50

-

45

-

40

•

35

30

25

20

O

.

••

15

Ld
*r

10

••

5

•-

0

••

-5

-+-

S
(VI

Figure 6

(VI

ru

(VI

(VI

PERCENT METRIZRMIDE

in
(VJ

CO
ru

NORMAL (1.3D

imam nrP gg iaf toittBfcttl with Rprard to Separation Denei^
o Major Basic Protein (MBP)
• EosinophU-derived Neurotoxin (EDN)

• EosinophU Cationic »ot;ia (ECP)

PERCENT METRIZAMIDE

Figure 8

NORMAL (1.57)

Qui*l*v DCP Big 1Q6 IssU^is with Regard to Separation. Density
o Major Basic Protein (MBP)
• Eosinophil Cationic Protein (ECP)

* Eosinophil-derived Neurotoxin (EDN;

PSRCsrrr jutrizamide

Figure 9

C

O

CD

a

M
tSJ

BTTMdouTsoa 90I ^d df;a suiBaSoaoT'ii

Percent Eosinophils of Eosinophils Recovered

NORMAL (1.68)

Qiumntvpcp uk 1q6 tealgamj with Regffrf1 t0 s^a^ti0^ d«ps*s
o Major Basic Protein (MBP)

• EosinophU Cationic Protein (ECP)
* Eosinophil-derived Neurotoxin (EDN)

PERCENT METRIZAMIDE

Figure 11

DIST OF EOS BY % METRIZ. (1.31)
65
60

t
•

55

-

sa

••

S 45

% 40
O

UJ 35
cn
o
u

38

'-

25

-

20

"

cn

°

15

* 10 I
5

••

0

..

-5
CD

in

(VI

O)
CM

OJ

CVI

CVJ

Figure 1

PERCENT METRIZRMIDE

CD

-

PATIENT (1.7*0

Quantity DCP per 106 Eosinophils with Regard to Separation D«ns3Ja
o Major Basic Protein (MBP)
• EosinophU Cationic Protein (ECP)
* EosinophU-derived Neurotoxin (EDN)

PERCENT METRIZAMIDE

Figure 12

6% in the 22% pool.

These same trends were observed in Patient #1

to a lesser degree.

While EDN levels in the four lighter fractions of Patient #2

were greater than MBP or ECP concentrations, the difference was
less pronounced than for other subjects (Fig.
increases

of both ECP and EDN in the

12).

The multifold

20 and 22% fractions

observed

in the other subjects was nonexistent in this patient.
Concentrations of MBP increased regularly from the 18%

interface, 26.99

4660.56
3).

32.65 ng/10

2012.30 ng/10

eosinophils, to the 25% interlace,

eosinophils, in normal subjects (Table

In both patients, the concentrations of MBP in the 18,

22% fractions were well

above

levels

found

in normals.

20, and

Values

for

MBP in the 23 and 24% layers were closer to normal values.

Eosinophil Cationic Protein concentrations increased from the

18% pool, 130.3
+

3985.6

134.9 ng/10° eosinophils.

2408.7 ng/10

increasing to 4176.4
(Table 4).
subjects'

6

+

The levels dropped to

eosinophils at the 23% interface before

2308.5 ng/10

6

eosinophils in the 25% layer

Concentrations of ECP were higher than the normal
range in the 18% pools for both patients.

exception of

With the

the 23% gradient of Patient #2, which was below the

concentration cf the normal subjects, all other ECP levels in the
20,

22,

23, and 24% pools were within the limits for the normal

subjects.

It should be noted that the values from Patient #1

tended to stretch the upper bound of the normal subject range,
while eosinophils from Patient #2 contained values nearer the
lower

limit.

between the

This
two

resulted

subiects.

in a

nine-fold maximum difference
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»a

cytapheresis to remove eosinophils, no patients have experienced
either harm or benefit as a result of eosinophil removal (Gleich

et al, 1983).

Gleich et al (1983) suggest this is due to the

ability of bone marrow to generate far greater numbers of
eosinophils than can be removed by current techniques.
A number of methods for purificaton of eosinophils have been

attempted, but most have produced nonviable cells, low yields, or

highly impure preparations (Behrens and Marti, 1954; Lindahl and
Lindahl, 1955; Behrens and Marti, 1955; Esselier and Marti, 1955;
Archer and Hirsch, 1963).

Eosinophils have been successfully

separated from other cells on the basis of cell adherence,

phagocytosis, autofluorescence, and cell density (Gleich et al,
1983).

Using a three step method, Parillo and Fauci (1978) have
obtained from normals, eosinophil slurries of 51-93% purity and

yields of 25-52%.

Granulocytes are separated first from

mononuclear cells by centrifugation over a Ficoll-Hypaque cushion
then from ertyhrocytes by dextran sedimentation and hypotonic

lysis.

The resulting granulocytes are then separated over a nylon

wool column which traps neutrophils and releases eosinophils.

A

modification of this technique was used by Parillo and Fauci

(1978) to produce 89-99% pure eosinophils with yields of 28-69%

from patients with eosinophilia.

Gleich et al (1983) have used

this procedure to separate eosinophils from contaminating
neutrophils in slurries obtained from guinea pig peritoneal
cavities, but were unable to separate eosinophils from neutrophils
of patients with eosinophilia.

MBP per 10 Eosinophils by Density Layer

.

~

1

'

1

NORMALS

PATIENTS

1

1.31

1.57

1.62

1.68

1.74

1.75

N.D.

2786.20

1108.92

152.10

4600.44

504.27

18*

5.50

59.48

32.98

20%

5.53

205.56

127.00

22%

47.32

43.89

1754.79

503.16|

2088.13

1853.09

23%

622.24

3946.98

4754.13

8940.2l|

2731.09

2992.82

24%

699.78

2957.84

5623.13

6339.5o|

9407.90

3837.25

25%

^876.19

2626.91

3793.00

7346.32I

Table 3

N.D.

N.D.

EDN per 10

Eosinophils by Density Layer

NORMALS

1.31

PATIENTS

1.57

1.62

1.68

1.74

N.D.

6461.47

4175.73

1.75

18%

1574.78

253.72

775.00

20%

3991.52

2046.83

7651.14

938.78

13139.20

3854.50

22%

32756.85

13103.28

30637.58

16456.32

15191.15

4745.52

23%

7583.12

6821.02

5417.70

21213.00

7526.15

4536.71

24%

10368.54

3633.78

17472.00

13264.81

13755.18

2751.19

25%

7292.54

1.0334.49

6753.17

17551.64

N.D.

Table 4

N.D.

ECP per 10

Eosinophils by Density Layer

NORMALS

1.31

1.57

PATIENTS

1.62

1.68

N.D.

2334.44

641.08

256.10

5389.65

590.38

11905.86 1 10786.85

909.38

1.74

1.75

18%

293.15

30.86

216.88

20%

1495.30

1095.56

7257.62

22%

12020.35

5005.62

31278.39

23%

2065.43

2690.85

3739.03

7446.89 1

4253.46

2180.19

24%

2805.16

1975.74

8189.18

3601.44 1

6605.79

1757.48

25%

1971.76

3118.59

4277.75

7337.35 1

Table 5

N.D.

N.D.

Eosinophil-derived neurotoxin concentrations increased

sharply to 23,238.5 + 9900.6 ng/10

eosinophils at the 22%

interface for normal individuals (Table 5).

Like ECP, the EDN in

the 23% pools was much less concentrated, 10,258.7
eosinophils.

+

6

7357.7 ng/10

Concentrations of EDN in the 24 and 25% fractions

were similar to the 23% pool.

Like those of normal subjects, the

eosinophils of Patient #1 demonstrated increased concentration of

EDN to the 22% pool, 15,191.2 ng/106 eosinophils. The level then
dropped to 7526.2 ng/10b eosinophils in the 23% fraction before
increasing to 13,755.2 ng/10b eosinophils in the 24% pool. Levels
of EDN in the Hypereosinophilic Syndrome patient, number two,
showed no increasing trends.

Rather, the levels remained

consistent between 2751.1 ng/10b eosinophils and 4745.5 ng/10
eosinophils throughout all gradients.

DISCUSSION

Although the number of subjects studied in this project was
limited, the information gathered from the study of their

eosinophils raises a number of possibilities.

Before addressing

these however, a brief review of the implications of the data is

pertinent.

The eosinophils of both normals and patients with

eosinophilia range from low density, those which migrated to the
18 or 20% Metrizamide gradient, to high density, those which

migrated to the 25% Metrizamide gradient.
a greater number of light density cells.

Patients tended to have
The concentration of MBP

tended to increase regularly with increased eosinophil density.

Eosinophil cationic protein and EDN conentrations increased to the
22% interface, then decreased before increasing to the 25%

gradient.

Finally, with respect to the corresponding layer of

normal eosinophils, those of patients showed neither a significant
decrease in protein level/10

cells nor a significant increase.

It has been suggested that the light eosinophils observed in

hypereosinophilic patients are the product of a degranulation
mechanism (Tai and Spry, 1981; Winqvist et al, 1982; Mahmoud and
Austin, 1980).

These authors indicate that a release of granule

contents accounts for the low density.

Further studies of

degranulation mechanisms have shown that degranulating mast cells
may release substances which have strong chemotactic attraction
for eosinophils (Beeson, 1980) and which unmask compliment

receptors on eosinophils thus "activating" the cells (Olsson and
Venge, 1979).

Winqvist (1982) also raises the possibility that

the cells represent an abnormal population, produced in the

marrow, with a lower granule content than normal.

Although the degranulation theory is more widely accepted,
the current study raises concerns regarding this mechanism. Unless
the cells undergo immediate degranulation following synthesis, one
would expect to find elevated numbers of normal density
eosinophils which have been produced but have not yet been
"activated".

Of a constant number of leukocytes applied to the

gradients, approximately the same number of "normal density"

eosinophils were recovered in the samples from patients as in
those from normals.

Also,

in eosinophil separation of an

eosinophilic patient following treatment with dehydroxy urea, no
"normal density" eosinophils were present (data not shown).

Is it not possible that the eosinophil acts by a combination
of the "abnormal population" and degranulation mechanisms?

If

this were the case, the marrow would, upon stimulation, produce a

large population of eosinophils which contain improperly formed
granules.

These cells, in that they are abnormal, may be

predisposed to degranulation inducing factors (eg. mast cell
degranulation products).

The marrow cells responsible for

producing "normal" eosinophils would continue to do so.

These

normal cells might be less disposed to degranulation accounting
for the normal eosinophil population observed in untreated

eosinophilic patients.

Dehydroxy urea, which supresses eosinophil

production by the bone marrow, would reduce this normal population
to near nonexistence following treatment.

Electrophoretic analysis of granule preparations have shown
MBP to compose 50% of the granule and ECP to compose 30% (Wassom
et al, 1981; Venge et al, 1980).

compose

Other constituents would then

20% of the eosinophil granule.

From this, the MBP

concentrations would be expected to be consistently highest, then
ECP, then EDN concentrations.

In those tested however, ECP and

EDN concentrations were consistently higher than MBP.

If

eosinophils do in fact degranulate, then it seems that protein
contents would be released in similar proportions to those
detected in the cell.

The proportions varied however, as

exemplified by the 22% peaks of ECP and EDN concentrations.
Together these discrepancies draw attention to the validity of the

testing method.

Is it possible that the RIAs for ECP and EDN are measuring

proteins other than the targeted proteins of the eosinophil? The
assays for these proteins were conducted using injection induced
antibodies. Alternatively, the MBP assay values were measured

using monoclonal antibodies.

Furthermore, the concentration of

ECP and EDN tend to correlate with the combined number of

neutrophils and eosinophils.

The 22% fraction which contained the

highest concentration of ECP and EDN also contained the largest
number of neutrophils.

Monoclonal antibodies to ECP and EDN have

now been developed and tests are underway to determine protein
content as measured by this technique.

If the concentrations as

measured by monoclonal RIAs correlate with the data presented in
this study, then tests must be performed to determine the basis
for the exceptionally high concentrations of ECP and EDN in the
22% layer.

Protein concentrations reported to date have been determined

on mixtures of eosinophils with a variety of densities (Venge et

al, 1983; Venge et al, 1980).

The difference between eosinophil

protein concentrations in the various density eosinophils is

significant enough to warrant that either a single density layer
be established as the standard for reported protein concentrations

or that cell density be reported in the literature whenever
discussing protein concentrations.
The concentration trends of MBP support the theory that

eosinophils degranulate in vivo.

In both normals and patients,

the protein concentration increased with increasing cell density.

Studies to determine causitive degranulation factors is curently
underway (Ackerman, personal communication).
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